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1 Musculoskeletal Research Group, Newcastle University, Newcastle upon Tyne, UK Background: OA affects over 200 million people across the globe and the number is only expected to increase over the next few decades. It is a health burden that involves the degradation and degeneration of the cartilage in the joints between the bones. The end point treatment is normally surgery after using a prosthetic implant to restore joint function. Thus, there is a need to focus on treatment approaches that can halt the progression of the disease at an earlier stage. Research involving cell therapies, especially using mesenchymal stem cells have gained a lot of interest owing to their ability to differentiate into various kinds of cells. However, they need to be supported with a system that allows them to survive and maintain their function. This was done with the help of biomaterials that have the ability to interact with biological systems around them. Methods: We aimed to use a method called the layer-by-layer (LBL) approach to modify biomaterial surfaces that would influence cell activity. We also aimed at fabricating micro-scale structures for using in the development of self-assembled matrices that would support cellular activity. LBL using the dip-coating method was used for both; modifying the biomaterial to create an extracellular matrix (ECM) like system with Type I Collagen and Hyaluronic Acid (Type I Coll/HA) for cells to organize themselves, as well as for developing self-assembled micro-tubes with PAH [FITC (poly allyl amine hydrochloride)] and PSS [poly (sodium-4-styrenesulphonate)] for providing support to the cells. The tubes were then fabricated with Streptavidin and were coated with complementary biotin oligonucleotides. The concept of strong bond between streptavidin-biotin bond was used to see if the tubes fabricated could be used for building scaffold like structures for cells to organize themselves. Results: On viewing the cells under the scanning electron microscope (SEM) we found that human mesenchymal stem cells had organized themselves on the complex ECM like matrix that was built for them and the biomaterial fabricated was able to influence cell behaviour. We also found that the micro structures fabricated had the potential to give rise to a cross-linked scaffold system that would support cell structure and activity. Conclusion: After having a look at the results and discussion it can be concluded that the human mesenchymal stem cells were found to have better adhesion to the complex matrix that was prepared by LBL. The fabricated micro tubes could possibly be used in the future to give rise to biomaterial scaffolds to influence cell behaviour and characteristics. The micro tubes did seem to have the potential to interact with the biological system surrounding them. 2 ). Methods: Data of patients aged over 50 years that attended for a dual energy X-ray absorptiometry scan at a UK district general hospital were collated. The population was divided according to BMI increments of 5 kg/m 2 . The prevalence of OP for each BMI category was ascertained. Logistic regression analysis was used to investigate for significant associations between BMI and OP prevalence, adjusted for age, sex and number of OP risk factors. Results: Data of 10 796 study subjects were collated (83.89% female). Mean age was 67.34 years. Decreasing prevalence of OP was associated with increasing BMI up to 40 kg/m 2 , above which increasing BMI was associated with increasing prevalence of OP (Table 1) Background: Bisphosphonates (BP) are first-line treatments for postmenopausal osteoporosis but long-term treatment may cause rare but serious side-effects (e.g. jaw osteonecrosis, atypical femoral fracture). Drug holidays may reduce the risks of these side-effects, after 3-5 years of BP treatment. We report the effect of discontinuation of alendronate treatment on bone turnover and fractures in an osteoporosis service setting. Methods: We measured urinary N-telopeptide crosslink of type I collagen (uNTx) in postmenopausal women who began an alendronate holiday between 2008 and 2012. Second-void, morning uNTx was measured by ELISA and corrected for urine creatinine (Cr). Fracture data were collected and evaluated in relation to bone health, excluding high-trauma fractures. Results: 85 women (mean [S.D.] age 70.1[9.1] years) had received a median (range) of 9 (4-19) years of alendronate. No subject had a NTx level above the manufacturer's premenopausal reference range (5-65 nM BCE/mM Cr) at discontinuation. Subjects were followed up for a median of 1.6 years post discontinuation. After approximately 1 year off treatment the uNTx level had risen above the premenopausal limit in 5/ 73 subjects (6.8%). Subjects were divided into those whose uNTX had changed less (Group A, n ¼ 30), or more (Group B, n ¼ 55) than the least significant change (LSC ¼ 28%) after discontinuing treatment. There was no difference in either age (70.1[9.1] vs 69.6[5.6]; P ¼ NS) or duration of bisphosphonate treatment (median 9 years in both groups; P ¼ NS). In Group A, there was no significant difference in uNTx levels at baseline, Year 1 or Year 2 (median 33.6; 33.4 and 32.4 respectively). The Group B baseline uNTx level was below that of Group A (median 22.9 vs 33.6; P < 0.001) but by Year 1 the uNTx level was higher (median 43.7 vs 33.4; P < 0.001). 7 patients reported a low trauma fracture during the follow-up period, 1 rib, 2 metatarsals, 2 pelvic fractures and 2 vertebrae. 3 fractures were adjudicated to be major osteoporotic fragility fractures. There was no difference in the incidence of osteoporotic fracture between the Groups A and B (3.3% vs 3.6%; 2 ¼ 0.942). In Group A only 1 subject had an osteoporotic fragility fracture, this subject was osteopaenic at the femoral neck, and osteoporotic at the spine. Both vertebral fractures occurred in Group B; one subject was osteoporotic at spine but osteopaenic at the femoral neck while the other was osteopaenic at both sites. Conclusion: uNTx levels rose above the premenopausal reference range in the first year in around 7% of subjects who ceased alendronate treatment, but individual uNTX levels either stay suppressed or rise, over a 2 year period. Early increases in uNTX might predispose to recurrent fracture, but overall fracture rates are low during bisphosphonate holidays. Background: Falls and fractures are a potentially preventable cause of morbidity in the elderly. Hip fractures, the most serious consequence of falls, are the impetus driving fracture prevention strategies. NICE recommends fracture risk assessment for all elderly patients and those with fracture risk factors. FRAX and QFracture are recommended, but use different risk factors. Notably, FRAX doesn't incorporate falls as a risk factor. We evaluated fracture risk factors and the predicted 10-year fracture risk of hip fracture patients at our centre. Methods: All patients admitted with hip fracture from December 2012 to April 2013 were included. Risk factors for fracture, previous fracture history and history of treatment with bone protection agents were evaluated. Potentially modifiable risk factors were defined as history of falls, previous fracture, known (untreated) osteoporosis, current smoker, daily average alcohol intake greater than 3units, current corticosteroid therapy and BMI <20 kg/m 2 . Fracture risk profiles were performed (looking at the predicted fracture risk prior to the hip fracture). Ten year risks of major osteoporotic and hip fracture were calculated using the FRAX calculator and QFracture2012. Results: Sixty-two patients were included in the study. A fall was the cause of hip fracture in 95% and a prior history of falls was seen in 45%. 31% had a previous history of fracture, 23% a low trauma fracture, and 8% had a personal history of hip fracture. Potentially modifiable risk factors were identified in 74%, and the mean number of modifiable risk factors was 1.9. Table 1 demonstrates the preadmission fracture risk assessment, using the FRAX and QFracture assessment tools. The score was calculated as if the patient's risk of fracture was being assessed prior to admission with a hip fracture. FRAX score could not be calculated for five patients aged over 90. A QFracture 2012 score could not be calculated for one patient aged over 100 years. Differences in predicted fracture risk score were compared with the Mann Whiney U test. Conclusion: The majority of patients admitted with hip fracture have potentially modifiable risk factors for fracture, and represent a missed opportunity for community fracture risk assessment, and subsequent initiation of bone-sparing treatment. Where no difference is seen in the predicted risk of major fracture, QFracture is more predictive of hip fracture. This may relate to the inclusion of falls as a risk factor for fracture. Background: A medical inpatient stay offers a window of opportunity for assessment of osteoporotic fracture risk and the initiation of appropriate bone protection in this high risk group. We aimed to assess current practice and improve the assessment of fracture risk and delivery of appropriate bone protection therapy on our unit. Methods: Questionnaires based on the online FRAX tool were completed on 60 inpatients >65 years on our general medical, gastroenterology and respiratory wards (20 per ward). Fracture risk was calculated using the online FRAX tool. The National Osteoporosis Guideline Group (NOGG) treatment recommendation, based on FRAX score, was obtained. Current bone protection therapy was compared against this treatment recommendation. We then introduced a bone health protocol for our general medical ward; admissions >65 years had a fracture risk assessment questionnaire completed at admission clerking. The clerking doctor calculated the FRAX fracture risk and NOGG treatment guidance. This information was used by the medical consultant to initiate appropriate therapy on the following ward round. A re-audit was conducted after 1 month. Results: Of 60 patients (35 women, 25 men), mean 10 year probability of major osteoporotic fracture was 24% (men 12%, women 32%) and mean 10 year probability of osteoporotic hip fracture was 16% (men 7%, women 22%). According to NOGG guidance, 19/60 (32%) of all patients and 18/35 (51%) of women should have been on bone protection therapy. 17/60 (28%) of all patients and 12/35 (34%) of women should have been referred for DEXA. Of the 60 patients, 9 were currently on bone protection (2 inappropriately according to NOGG guidance). Only one patient had been referred for DEXA. At re-audit on the general medical ward, of 10 patients (6 women, 4 men), mean 10 year probability of major osteoporotic fracture was 24% (men 11%, women 33%) and mean 10 year probability of osteoporotic hip fracture was 15% (men 5%, women 22%). According to NOGG guidance, 3/10 (30%) of all patients and 3/6 (50%) of women should have been on bone protection therapy. 3/10 (30%) patients and 2/6 (33%) of women should have been referred for DEXA. Of the 10 patients, all were on correct bone protection therapy. All patients who required DEXA had this requested if appropriate. Conclusion: Elderly medical inpatients are at significant risk of osteoporotic fracture and this appears largely unrecognized and under-treated. Fracture risk assessment can be easily carried out on the ward as part of the routine admission clerking. Our ward-based bone health protocol was straightforward to implement and improved the proportion of patients on correct bone protection from 37% to 100% and those having an appropriate DEXA scan from 6% to 100%. Disclosure statement: The authors have declared no conflicts of interest.
